In November 1996, the Wall Street Journal reported that EliLilly was paying homeless alcoholics from a local shelter toparticipate in safety testing of new drugs at its trial sitein Indianapolis.1 "These individuals want to help society,"asserted Lilly's director of clinical pharmacology. The subjects,however, said they took part for easy money and free room andboard. Although Lilly reportedly offered the lowest per diemin the business, it managed to attract poor subjects from allover the country.1 The medical director of the local HomelessInitiative Program said Lilly had created a "shadow economy"of paid . . . [Full Text of this Article]
Source Information
Dr. Elliott is a professor at the Center for Bioethics at the University of Minnesota, Twin Cities. Dr. Abadie is an anthropologist and independent scholar who recently completed a research fellowship in the Bioethics Research Program, Mayo Clinic, Rochester, MN.
This article has been cited by other articles:
Dresser, R.
(2009). First-in-Human Trial Participants: Not a Vulnerable Population, but Vulnerable Nonetheless.. J Law Med Ethics
37: 38-50
Arai, R. J., Hoff, P. M. G., de Castro, G. Jr., Stern, A.
(2009). Ethical Responsibility of Phase 0 Trials. Clin. Cancer Res.
15: 1121-1121
[Full Text]
Previous
